陸曉霞
【摘要】目的:分析孟魯司特鈉聯(lián)合布地奈德對(duì)小兒咳嗽變異性哮喘的療效及肺功能改善的作用。方法:從本院收治的小兒咳嗽特異性哮喘患兒中選取70例,利用隨機(jī)數(shù)表法分兩組。對(duì)照組布地奈德治療,試驗(yàn)組孟魯司特鈉聯(lián)合布地奈德治療。比較兩組的治療情況。結(jié)果:試驗(yàn)組治療總有效率高于對(duì)照組(P<0.05)。治療后,兩組FEV1、FVC、PEFR、PaO2、SaO2高于同組治療前,PaCO2低于同組治療前(P<0.05)。組間對(duì)比,試驗(yàn)組FEV1、FVC、PEFR、PaO2、SaO2高于對(duì)照組,PaCO2低于對(duì)照組(P<0.05)。結(jié)論:在小兒咳嗽特異性哮喘治療中,孟魯司特鈉聯(lián)合布地奈德治療效果顯著。
【關(guān)鍵詞】哮喘;咳嗽;小兒;肺功能
Efficacy and lung function improvement of montelukast sodium combined with budesonide in children with cough variant asthma
LU Xiaoxia
Qingyang Hospital of Jiangyin, Jiangyin, Jiangsu 214400, China
【Abstract】Objective: To analyze the efficacy of montelukast sodium combined with budesonide in children with cough variant asthma and the effect of improving lung function. Methods: 70 children with cough variant asthma in our hospital were selected and divided into two groups by random number table method. The control group was treated with budesonide, and the experimental group was treated with montelukast sodium combined with budesonide. The treatment conditions of the two groups were compared. Results: The total effective rate of treatment in the experimental group was higher than that in the control group(P<0.05). After treatment, the FEV1, FVC, PEFR, PaO2 and SaO2 of the two groups were higher than those before treatment, and PaCO2 was lower than that before treatment in the same group(P<0.05). Compared between groups, FEV1, FVC, PEFR, PaO2, SaO2 in the experimental group were higher than those in the control group, and PaCO2 was lower than that in the control group(P<0.05). Conclusion: In the treatment of cough variant asthma in children, montelukast sodium combined with budesonide has a significant effect.
【Key Words】Asthma; Cough; Children; Lung function
小兒咳嗽特異性哮喘臨床發(fā)病率較高,是一種特殊類型哮喘,發(fā)病后出現(xiàn)咳嗽癥狀,且反復(fù)發(fā)作,引起氣道高反應(yīng)性狀態(tài),通常在夜間或清晨發(fā)作,若控制不當(dāng)會(huì)導(dǎo)致慢性咳嗽,嚴(yán)重影響患兒生長(zhǎng)發(fā)育,且此疾病具有隱匿性發(fā)作的特點(diǎn),治療難度較高[1-3]。目前針對(duì)小兒特異性哮喘患兒,臨床無特效治療方式,多以藥物治療為主,可緩解患兒病情,但其中抗菌藥物應(yīng)用較多,長(zhǎng)期使用會(huì)產(chǎn)生耐藥性,導(dǎo)致病情遷延不愈,因此臨床重視找尋更為高效的用藥方案,其中布地奈德和孟魯司特鈉應(yīng)用價(jià)值較高,聯(lián)合給藥效果值得進(jìn)一步探究[4-6]。本文分析了孟魯司特鈉聯(lián)合布地奈德對(duì)小兒咳嗽變異性哮喘的療效及肺功能改善作用,報(bào)道如下。
1.1 一般資料
2020年1月—2021年12月,從本院收治的小兒咳嗽特異性哮喘患兒中選取70例,利用隨機(jī)數(shù)表法分兩組,各35例。對(duì)照組,男19例,女16例,年齡2~11歲,平均年齡(6.54±1.31)歲,病程1~6周,平均病程(3.74±1.01)周,疾病分級(jí):1級(jí):13例,2級(jí):15例,3級(jí):5例,4級(jí):2例;試驗(yàn)組,男21例,女14例,年齡3~10歲,平均年齡(6.76±1.11)歲,病程2~7周,平均病程(3.87±1.02)周,疾病分級(jí):1級(jí):11例,2級(jí):13例,3級(jí):6例,4級(jí):5例。上述資料,組間均衡性良好,可比。納入標(biāo)準(zhǔn):①哮喘急性發(fā)作期患兒;②具有咳嗽特異性哮喘典型癥狀患兒;③家長(zhǎng)對(duì)研究知情且自愿參與。排除標(biāo)準(zhǔn):①合并藥物過敏史患兒;②伴有免疫系統(tǒng)疾病患兒;③糖皮質(zhì)激素依賴史患兒;④合并其他喘息性疾病患兒;⑤伴有先天性心臟病等先天缺陷患兒。
1.2 方法
[2] 周建,遲春天.布地奈德福莫特羅粉吸入劑聯(lián)用孟魯司特鈉治療咳嗽變異性哮喘的療效及對(duì)肺功能的影響[J].中國(guó)醫(yī)刊,2021,56(11):1200-1203.
[3] 趙海峰.孟魯司特鈉聯(lián)合布地奈德治療小兒咳嗽變異性哮喘的臨床療效[J].中國(guó)藥物與臨床,2021,21(10): 1713-1715.
[4] 王寬鋒,任華,王翠翠,等.孟魯司特鈉聯(lián)合布地奈德霧化吸入對(duì)咳嗽變異性哮喘患兒肺功能的影響[J].實(shí)用臨床醫(yī)藥雜志,2019,23(4):41-43,46.
[5] 丁臻博,魯萍,黃永坤,等.孟魯司特鈉與西替利嗪聯(lián)合布地奈德治療兒童咳嗽變異性哮喘臨床效果,肺功能及安全性[J].昆明醫(yī)科大學(xué)學(xué)報(bào),2020,41(3):86-90.
[6] 林麗麗.布地奈德鼻噴霧劑聯(lián)合孟魯司特鈉片治療兒童咳嗽變異性哮喘的療效觀察及對(duì)相關(guān)因子的影響[J].中國(guó)婦幼保健,2018,33(11):2480-2483.
[7] 侯俊榮.布地奈德聯(lián)和孟魯司特鈉治療咳嗽變異性哮喘對(duì)肺功能指標(biāo)與免疫球蛋白E和腫瘤壞死因子-α的影響[J].中國(guó)臨床醫(yī)生雜志,2019,47(5):535-538.
[8] 唐文慧,張偉,李春梅,等.布地奈德福莫特羅聯(lián)合孟魯司特鈉治療支氣管哮喘的療效及對(duì)炎癥因子水平的影響[J].醫(yī)學(xué)綜述,2020,26(12):2493-2497.
[9] 李俊梅,鄭成中.布地奈德聯(lián)合孟魯司特鈉對(duì)兒童支氣管哮喘患兒肺功能、T細(xì)胞免疫功能的影響[J].實(shí)用臨床醫(yī)藥雜志,2018,22(23):26-28,32.
[10] 劉清,盧志威,辛淑君,等.布地奈德聯(lián)合孟魯司特鈉治療支氣管哮喘的有效性和安全性及對(duì)肺功能的影響[J].基因組學(xué)與應(yīng)用生物學(xué),2020,39(2):948-954.
[11] 黃莉,魯利群,汪燕,等.布地奈德聯(lián)合孟魯司特鈉治療哮喘兒童的臨床效果及對(duì)患兒免疫功能,Cys LTs及FLAP表達(dá)的影響[J].現(xiàn)代生物醫(yī)學(xué)進(jìn)展,2019,19(3): 544-547.
[12] 楊麗煒,榮慶娜,馮蘭英,等.孟魯司特鈉聯(lián)合布地奈德吸入治療小兒哮喘的效果及對(duì)氣道功能,血清炎性因子的影響[J].臨床誤診誤治,2019,32(10):23-26.
[13] 張志琴,羅孝斌.孟魯司特鈉聯(lián)用布地奈德對(duì)支氣管哮喘患兒療效分析[J].中國(guó)藥物與臨床,2021,21(11): 1899-1901.
[14] 黃莉,魯利群,寧雪梅,等.布地奈德吸入聯(lián)合孟魯司特鈉對(duì)小兒哮喘氣道功能及血清炎癥因子的影響[J].海南醫(yī)學(xué)院學(xué)報(bào),2018,24(1):64-66,70.